Trial | N randomized/evaluable | Treatment arms (dose) and schedule | Duration |
---|---|---|---|
Berry, 2002 [69] | 120/119 | mitoxantrone (12 mg/m2) iv q 3 wks prednisone (5 mg) po twice daily | 6 cycles |
 |  | prednisone (5 mg) po twice daily |  |
Kantoff, 1999 [70] | 242/242 | mitoxantrone (14 mg/m2) iv q 3 wks hydrocortisone (40 mg) po daily (two divided doses) | hydrocortisone to progression or treatment failure |
 |  | hydrocortisone (40 mg) po daily (two divided doses) |  |
Tannock, 1996 [71] | 161/161 | mitoxantrone (12 mg/m2) iv q 3 wks prednisone (5 mg) po twice daily | mitoxantrone to dose of 140 mg/m2, continuing on prednisone |
 |  | prednisone (5 mg) po twice daily |  |
Weissbach, 1998 [88] | NR/175 | epirubicin (25 mg/m2) iv q mo | NR |
 |  | EMP (560 mg) daily |  |
 |  | mitomycin C (10 mg/m2) iv q mo |  |
Anderström, 1995 [72] | 149/145 | epirubicin (20 mg/m2) iv q wk MPA (500 mg) po twice daily | epirubicin to dose of 1000 mg/m2, MPA to progression |
 |  | EMP (12 mg/kg) po daily (two divided doses) |  |
Laurie, 1992* [73] | 145/142 | In combination: 5-FU (600 mg/m2) iv q 4–5 wks doxorubicin (30 mg/m2) iv q 4–5 wks mitomycin-C (10 mg/m2) iv q 4–5 wks†| to progression |
 |  | In sequence: 5-FU (500 mg/m2) iv q 5 wk doxorubicin (50 mg/m2) iv q 3–4 wk mitomycin-C (12.5 mg/m2) iv q 4 wk |  |
Saxman, 1992 [74] | 103/103 | cyclophosphamide (500mg/m2)‡ iv q 3 wks doxorubicin (50mg/m2)‡ iv q 3 wks methotrexate (40mg/m2)‡ iv q 3 wks | to progression, doxorubicin not to exceed dose of 450mg/m2 |
 |  | cyclophosphamide (1000 mg/m2)§iv q 3 wks |  |
Murphy, 1988 [75] | 180/152 | doxorubicin (50 mg/m2) iv q 3 wks cyclophosphamide (500 mg/m2) iv q 3 wks | to progression |
 |  | cisplatin (50 mg/m2) iv q 3 wks 5-FU (500 mg/m2) iv q 3 wks cyclophosphamide (500 mg/m2) iv q 3 wks |  |
 |  | methotrexate (100 mg/m2) iv (2 divided doses) q 2 wks |  |
Stephens, 1984 [76] | 158/137 | doxorubicin (40 mg/m2)¶iv q 3 wks cyclophosphamide (200 mg/m2)¶iv q 3 wks | doxorubicin to dose of 450 mg/m2, continuing on cyclophosphamide or hydroxyurea to progression |
 |  | hydroxyurea (3600 mg/m2) po twice q wk |  |